CORONA Remedies Limited commences commercial production at EU-GMP hormone facility
Corona Remedies · Pharmaceuticals & Biotechnology
Key highlights
- On June 30, 2026, CORONA Remedies inaugurated and started commercial production at its EU-GMP approved Women's Hormone manufacturing facility in Bhayla, Ahmedabad.
- The facility covers 1.0 lakh sq. ft. with an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels and will increase hormone manufacturing capacity by nearly 20%.
- CORONA Remedies is a Top 30 Indian pharmaceutical company specializing in women’s healthcare and other therapeutic areas, operating WHO GMP/EU GMP-certified manufacturing sites and DSIR-approved R&D centers.
Why it's rated notable: The filing states commencement of commercial production and a nearly 20% expected rise in in-house hormone capacity, but gives no capex amount, so the level is medium.
Original filing
Commencement Of Commercial Production
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Corona Remedies
- Acquisition / mergerNotableCORONA Remedies acquires Wokadine® brand from Dr. Reddy’s Laboratories
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.